BACKGROUND: Proton pump inhibitors (PPIs) and histamine type 2 receptor blockers (H2Bs) are used for stress ulcer prophylaxis. Although the PPIs have greater potency for acid suppression, their relative effectiveness for preventing clinically important GI bleeding (CIGIB) has not been established. The goal of this study was to determine whether prophylactic PPIs were associated with lower risk of CIGIB than H2Bs among critically ill adults.
Proton pump inhibitors (PPIs) and histamine type 2 receptor blockers (H2Bs) are the main stress ulcer prophylactic agents prescribed by critical care providers. The 1999 American Society of Health-System Pharmacists' guidelines that recommended H2Bs 1 are discordant with subsequent meta-analyses that favored PPIs. [2] [3] [4] [5] [6] Methodologic flaws of the studies that were included in these meta-analyses 3 raised important concerns regarding which of these alternative therapies are superior in terms of preventing bleeding in critical care practice. Serious questions regarding recommendations that favor PPIs were raised by a 2014 observational study of 35,312 patients. 7 This study reported that PPIs were associated with a higher risk of GI bleeding (OR, 2.24 [95% CI, 1.81-2.76]) than H2Bs. However, this study also had some concerning limitations; it included GI bleeding episodes that did not meet accepted definitions for being clinically important. 8, 9 In addition, its estimates of the protective effects of H2Bs could have been inflated due to higher acuity of the group that received PPIs and the fact that the type of prophylactic agent clustered according to ICU. In addition to concerns that PPIs may not be superior to H2B for preventing bleeding events, recent cost-effectiveness analyses that assume that PPIs have a better ability to prevent bleeding have found prophylaxis with H2Bs to be more cost-effective than prophylaxis with PPIs. 10 We performed a multicenter study in a geographically dispersed population of adults cared for in US nonfederal ICUs that had near-universal adherence to guidelines for stress ulcer prophylaxis (98%). 11 Although stress ulcer prophylaxis was nearly always prescribed for high-risk patients, some at-risk patients did not receive 3 days of prophylaxis due to extubation, resolution of sepsis, or for other reasons. The choice of a PPI or an H2B was sufficiently heterogeneous to allow comparative effectiveness analyses of their association with clinically important GI bleeding (CIGIB). The study design included adjustment for acuity that is specific for critically ill adults, analytical methods that balance measured factors which differed among the groups, and techniques which account for unknown factors that cluster with the prophylaxis-prescribing habits of individual ICUs.
Patients and Methods

Data
The data security, structure, sources, and characteristics of the Philips eICU Research Institute data repository have been previously described. 12, 13 Briefly, this repository is a de-identified electronic clinical database that contains physical examination, laboratory result, clinical diagnosis, treatment, and vital signs variables from adult patients of geographically dispersed US nonfederal hospitals. Selection of disease diagnoses was performed through a menu of discrete diagnosis strings that are linked to individual International Classification of Diseases, Ninth Revision (ICD-9), codes. Health severity was measured according to the Acute Physiology and Chronic Health Evaluation version IV (APACHE-IV) score.
14 Data security was certified by Privacert, Inc, as meeting safe harbor standards. Institutional review board evaluation (Human Subjects Review #12513) resulted in a waiver of the requirement for informed consent in accordance with the 45th Code of Federal Regulations 164.514 (b) (1) (i).
Inclusion and Exclusion Criteria
Between January 1, 2008, and June 30, 2012, patients were included who received a PPI or H2B with at least one of the following stress ulcer risk factors: mechanical ventilation > 24 h, coagulopathy, head injuries, major burns, sepsis, corticosteroid therapy > 250 mg of hydrocortisone or equivalent daily, acute renal failure, hepatic failure, transplantation, neurological injuries, hypotension, surgery, trauma, or ICU length of stay (LOS) > 1 week.
Exclusion criteria included ICU LOS < 72 h, GI bleeding within the first 72 h of admission, receipt of a PPI or H2B for < 3 days prior to an episode of CIGIB, concomitant or consecutive use of PPIs and H2Bs, or patients with missing platelet counts, admission source, or teaching hospital status.
Measures
The dependent variable was CIGIB. Episodes of GI bleeding were defined through the ICD-9 code 578 that encompassed hematemesis, blood in stool, and unspecified bleeding. Only one entry with the aforementioned code was required to define a bleeding episode. Diagnosis strings were used to exclude bleeding due to other causes such as "postpartum hemorrhage" within the aforementioned ICD-9 code. CIGIB episodes were defined in accordance with the definition of Cook et al, 8, 9 after slight modification, as the occurrence of any of the following: (1) an absolute reduction in systolic blood pressure by at least 20 mm Hg; (2) reduction in diastolic blood pressure by at least 10 mm Hg; (3) heart rate increase by at least 20 beats/min; or (4) administration of a blood transfusion. The main independent variable was receipt of a PPI vs an H2B for at least 3 days before an episode of CIGIB.
The following covariates were included in the multivariable model: demographic characteristics (age, sex, and race); clinical variables (stress ulcer risk factor(s) as defined earlier, cancer, HIV, cirrhosis, enteral nutrition receipt, and intubation in the first day); medications that affect bleeding risk, including antiplatelet agents, anticoagulants, thrombolytics, nonsteroidal antiinflammatory drugs, sucralfate, and antacids; admission source; physician specialty; teaching hospital status; and APACHE-IV score.
Statistical Analyses
Univariable and bivariable analyses were used to describe the variables and their distributions and to compare the two treatment groups by using c 2 tests for categorical variables and t tests for continuous variables, respectively. A Cox proportional hazards model was fit to estimate the relative hazard of CIGB among patients exposed to at least 3 days of a PPI compared with patients exposed to at least 3 days of an H2B using patient-day observations. Patients were censored when they were discharged from the ICU.
Because treatment selection was nonrandom, propensity score matching (PSM) and instrumental analysis were used to make comparisons among groups with similar distributions of measured factors and to account for unmeasured covariates that track with stress ulcer prophylaxis-prescribing habits of their ICU, respectively.
Propensity Score Matching
In a multivariable logistic regression model, the propensity scores for those receiving 3 days of a PPI or 3 days of an H2B were determined by using the demographic characteristics, ICU type, enteral nutrition, cancer, HIV, cirrhosis, neutropenia, platelet count, immunosuppression, stress ulcer risk factors, sucralfate, antacids, anticoagulants, antiplatelets, thrombolytics, nonsteroidal antiinflammatory drugs, admission source, physician specialty, and APACHE-IV score. One-to-one matching with no replacement and a caliper of 0.00001 were then used to create matched groups. Covariate balance prior to and following matching was assessed by using t tests, accounting for matching design, and the standardized mean difference approach. 15 If the P value of the t test was < .05 and the standardized mean difference was > 10%, the covariate was then considered imbalanced between the two groups and was therefore included in the final model. Lastly, we estimated exposure effect on the hazard of CIGIB by using Cox modeling.
Instrumental Variable Analyses
An instrumental variable approach that used the two-stage residual inclusion method 16 was used to account for some unmeasured variables. The instrumental variable approach facilitates comparisons between intervention and control groups that are otherwise comparable by using an instrument to determine group assignment within a nonrandomized design. A valid instrumental variable has two characteristics: first, it must be strongly correlated with exposure; second, it should not be correlated with the unobserved variables that influence the outcome in the error term. 17 Observing that an extremely high proportion of patients from an ICU are exposed to a PPI rather than to an H2B suggests that prescribing decisions may be dependent on ICU prescribing practices rather than individual patient characteristics. Consequently, the preferred therapeutic class for the patient's ICU can be used as an instrumental variable. We classified ICUs that prescribed PPIs to at least 90% of their patients as PPI preference units. The first stage of the model was validated by demonstrating that the PPI preference variable was strongly correlated with the exposure (ie, the receipt of PPIs for 3 days [adjusted OR, 13.4 (95% CI, 10.9-16.5)]).
Sensitivity Analyses
Multiple case reports have suggested that PPIs may be associated with thrombocytopenia. [18] [19] [20] [21] [22] Because coagulopathy from post-PPI thrombocytopenia was identified as a plausible explanation for the higher risk of bleeding associated with PPIs, 7 we included testing post-PPI thrombocytopenia as a possible explanatory factor in our prespecified analyses.
Lastly, history of gastric ulcer or bleeding has been identified as a stress ulcer risk factor 1 that was not available in our dataset. This unmeasured risk factor could act as a confounder and could also have been a factor influencing treatment selection because chestjournal.org patients with these two conditions are more likely to be treated with PPIs than with H2Bs. We used the approach of Lin et al 23 for assessing the impact of this unmeasured potential confounder in sensitivity analyses. This analysis was accomplished by adjusting the observed estimate by the prevalence of the unmeasured confounder in the PPI group and the H2B group and the effect of the unmeasured confounder on CIGIB using a simple formula.
A series of other sensitivity analyses and their rationale are presented in Table 1 .
All analyses accounted for ICU clustering effect by using a robust variance estimator. Data preparation was performed by using SAS version 9.3 (SAS Institute, Inc), and Stata version 11 was used for data analyses (StataCorp LP).
Results
In the present study, 70,093 patients contributed a total of 356,147 patient-days of observation. Exposure to 3 days of a PPI (70.7%) was more common than exposure to a H2B (29.3%). Almost 76% of the sample was white, and 54% was male. The most common stress ulcer risk factor was mechanical ventilation (60%). There were 424 cases of new CIGIB (0.6%) among critically ill adults exposed to at least 3 days of a PPI or H2B. The incidence rate of CIGIB in this cohort was 1.2 cases per 1,000 patient-days (95% CI, 1.08-1.31). More than 50% of patients received anticoagulants, antiplatelets, or nonsteroidal antiinflammatory drugs during their ICU stay (Table 2) . After exclusion of patients with LOS < 72 h, the average LOS was 9.9 days while the median was 7 days.
The Cox model ( Figure 1 summarize the association between PPIs, H2Bs, and CIGIB.
Lastly, we explored the effect of an unmeasured confounder, such as history of GI ulceration or bleeding, by using the approach of Lin et al. 23 A range of possible prevalences is presented in Table 4 along with HRs for an unmeasured confounder. In nearly all scenarios, H2Bs were either superior or equivalent to PPIs in their ability to prevent CIGIB. PPIs were superior to H2Bs only under extreme and clinically implausible scenarios. The HR for an unmeasured confounder (eg, history of GI ulceration or bleeding) must be at least 3.0 and present in at least 90% of patients receiving a PPI while not being present in any patient who received an H2B. In this implausible scenario, the approach of Lin et al 23 estimates that PPIs may be associated with lower risk of CIGIB compared with H2Bs (HR, 0.7 [95% CI, 0.52-0.94]), and when the HR of the unmeasured confounder was reduced to 2, PPIs were no longer superior to H2Bs.
Discussion
We found that CIGIB was less common (0.6%) than reported for clinical trial subjects who received stress ulcer prophylaxis. 3, 5, 6 The lower event rates may reflect a reduction in hypoperfusion-related factors that lead to the mucosal stress and breakdown that precedes GI bleeding from a stress ulcer. Improvements in critical care practice include more adequate and timely resuscitation, effective and optimally timed enteral nutrition, and more rapid initiation of measures to Prophylaxis with a PPI for at least 3 days was associated with higher CIGIB risk (HR, 1.97 [95% CI, 1.48-2.63]) than prophylaxis with an H2B. This study was larger and also supports the veracity of the association of greater effectiveness of H2Bs than PPIs for the prevention of CIGIB observed in a previous epidemiological study. 7 Interestingly, outcomes observed in clinical practice seem to be divergent from the findings of five prior reports that compared bleeding prophylaxis efficacy of PPIs and H2Bs. Figure 1 -Hazard ratios for stress ulcer prophylaxis (proton pump inhibitors vs histamine type 2 receptor blockers) associated clinically important GI bleeding using different analytical methods. study of clinical practice is substantially lower than the rates of 2.2% to 3.3% reported from clinical trials. It is also lower than the 2.1% bleeding rate reported by a previous epidemiological study. 7 This earlier study reported all bleeding rather than selectively reporting CIGIB, as was done in the present article.
Another factor is the relatively small size of the clinical trials compared with the clinical practice outcomes studies. Large clinical outcomes trials include a broader spectrum of patients than randomized trials because they include more sites and use markedly less restrictive exclusion criteria. A third factor relates to advances in resuscitation and organ support that occurred since the completion of the randomized trials that may affect the relative responsiveness of the population to the alternative therapies. This concept is grounded on the hypothesis that better resuscitated patients with less severe mucosal damage may have a greater capacity to respond to H2B prophylaxis than PPI prophylaxis. Because CIGIB events were noted for both groups, future personalized critical care studies will be required to identify individual patients who would achieve better prophylaxis from a PPI than from an H2B. These findings provide the basis for the design of future studies that could allow the selection of a prophylactic agent based on characteristics that are unique to the individual patient.
The findings of association of greater effectiveness of H2B prophylaxis than PPI prophylaxis are highly internally consistent and robust. We were unable to attribute the difference to variations in acuity by adjustment or PSM analysis. In the present study, 2 days of exposure yielded results similar to 3-day exposure (HR, 2.10 [95% CI, 1.65-2.67]). This result was similar to the study by MacLaren et al, 7 which found that PPI use for 2 days was associated with higher odds of GI bleeding compared with H2Bs (OR, 2.24 [95% CI, 1.81-2.76]). Propensity analyses produced similar findings, suggesting that the differences in outcomes were not due to imbalance of the extensive set of measured factors. Additional analyses that examined the role of PPI associated thrombocytopenia, the effects of medications on PPI or H2B pharmacokinetics, and other interactions failed to identify a confounding factor. Furthermore, sensitivity analyses indicated similar results under a wide variety of scenarios for a potent unmeasured confounder such as prior ulceration or bleeding (Table 4 ).
The present study has strengths and important limitations. First, the use of statistical approaches that assessed for confounding by imbalance of known factors, as well as unknown factors related to the tendency of an ICU to preferentially prescribe a PPI, provided consistent estimates of the comparative effectiveness of the alternative methods of prophylaxis for CIGIB. However, these analyses do not prove that such a factor was not present. The study design does not allow insight into episodes of blood loss that do not meet the criteria of Cook et al 8, 9 for being clinically important.
However, the availability of physiological measures allowed a more precise definition of clinically significant bleeding events than the ICD-based measures used for previous epidemiological studies. We were unable to perform analyses stratified according to route of administration, and differences in rates of IV administration could have affected effectiveness. IV administration of H2Bs to this group with a nonfeeding rate of 41% may have been modestly higher than the PPIs group, which had a nonfeeding rate of 36%. It does not seem likely that differences attributable to this factor were large because the rapid absorption of enteral H2Bs 27 and PPIs 28 corresponds to theoretical AUC differences of only 1% of IV PPIs over oral PPIs and a 4% difference for IV H2Bs compared with enteral H2Bs over the 72-h administration period. The key limitation is that the exposure to the prophylactic agent (PPI vs H2B) was not randomly assigned.
Conclusions
CIGIB is an uncommon outcome among critically ill adults who received stress ulcer prophylactic agents. Unlike findings from clinical trials, PPIs were associated with higher risk of CIGIB compared with H2Bs in clinical practice. The robust association of H2Bs with fewer episodes of CIGIB in a second large clinical practice cohort supports the conclusions of costeffectiveness studies that favor the use of an H2B over a PPI for stress ulcer prophylaxis in at-risk critically ill adults.
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